Journal
CLINICAL CANCER RESEARCH
Volume 28, Issue 10, Pages 1999-2019Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1078-0432.CCR-21-3058
Keywords
-
Categories
Funding
- Cancer Research UK
- Cancer Research UK Manchester Institute [A27412]
- Manchester CRUK Centre Award [A25254]
- CRUK Lung Cancer Centre of Excellence [A20465]
- CRUK Manchester Experimental Cancer Medicines Centre [A25146]
- CRUK
Ask authors/readers for more resources
Poorly differentiated neuroendocrine carcinomas (PD-NEC) are rare cancers that have gained attention due to improved diagnostic methods and the phenomenon of NE lineage plasticity. However, effective treatment options for PD-NEC patients are challenging due to the lack of targetable molecular drivers, limited preclinical models, and validated biomarkers.
Poorly differentiated neuroendocrine carcinomas (PD-NEC) are rare cancers garnering interest as they become more commonly encountered in the clinic. This is due to improved diagnostic methods and the increasingly observed phenomenon of NE lineage plasticity, whereby nonneuroendocrine (non-NE) epithelial cancers transition to aggressive NE phenotypes after targeted treatment. Effective treatment options for patients with PD-NEC are challenging for several reasons. This includes a lack of targetable, recurrent molecular drivers, a paucity of patient-relevant preclinical models to study biology and test novel therapeutics, and the absence of validated biomarkers to guide clinical management. Although advances have been made pertaining to molecular subtyping of small cell lung cancer (SCLC), a PD-NEC of lung origin, extra pulmonary (EP)-PD-NECs remain understudied. This review will address emerging SCLC-like, same-organ non-NE cancer-like and tumor-type-agnostic biological vulnerabilities of EP-PD-NECs, with the potential for therapeutic exploitation. The hypotheses surrounding the origin of these cancers and how NE lineage plasticity can be leveraged for therapeutic purposes are discussed. SCLC is herein proposed as a paradigm for supporting progress toward precision medicine in EP-PD-NECs. The aim of this review is to provide a thorough portrait of the current knowledge of EP-PD-NEC biology, with a view to informing new avenues for research and future therapeutic opportunities in these cancers of unmet need.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available